BACKGROUND: IL28B polymorphisms are predictors of therapy response in hepatitis C virus (HCV) patients. We do not know whether they are markers of treatment response in admixed populations or not. AIMS: To determine whether IL28B polymorphisms are predictors of therapy response in patients with HCV from an admixed population and are influenced by genetic ancestry. METHODS: rs12979860 and rs8099917 were genotyped in 222 HCV patients treated with pegylated interferon and ribavirin. Ancestry was determined using genetic markers. RESULTS: IL28B rs12979860 C/C was associated with sustained virological response (SVR), whereas C/T and T/T were associated with failure to therapy (P = 1.12 × 10(-5) ). IL28B rs8099917 T/T was associated with SVR, and G/G and G/T were associated with nonresponse/relapse (NR/R) (P = 8.00 × 10(-3) ). Among HCV genotype 1 patients with C/C genotype, genomic ancestry did not interfere with therapy response. Among patients with rs12979860 T/T genotype, African genetic contribution was greater in the NR/R group (P = 1.51 × 10(-3) ), whereas Amerindian and European genetic ancestry contribution were higher in the SVR group (P = 3.77 × 10(-3) and P = 2.16 × 10(-2) respectively). Among HCV type 1 patients with rs8099917 T/T, African genetic contribution was significantly greater in the NR/R group (P = 5.0 × 10(-3) ); Amerindian and European ancestry genetic contribution were greater in the SVR group. CONCLUSION: IL28B rs12979860 and rs8099917 polymorphisms were predictors of therapy response in HCV genotypes 1, 2 and 3 subjects from an admixed population. Genomic ancestry did not interfere with response to therapy in patients with rs12979860 C/C, whereas it interfered in patients with C/T and T/T genotypes. Among HCV genotype 1 rs8099917 T/T patients, genomic ancestry interfered with response to therapy.
BACKGROUND:IL28B polymorphisms are predictors of therapy response in hepatitis C virus (HCV) patients. We do not know whether they are markers of treatment response in admixed populations or not. AIMS: To determine whether IL28B polymorphisms are predictors of therapy response in patients with HCV from an admixed population and are influenced by genetic ancestry. METHODS:rs12979860 and rs8099917 were genotyped in 222 HCVpatients treated with pegylated interferon and ribavirin. Ancestry was determined using genetic markers. RESULTS:IL28Brs12979860 C/C was associated with sustained virological response (SVR), whereas C/T and T/T were associated with failure to therapy (P = 1.12 × 10(-5) ). IL28Brs8099917 T/T was associated with SVR, and G/G and G/T were associated with nonresponse/relapse (NR/R) (P = 8.00 × 10(-3) ). Among HCV genotype 1 patients with C/C genotype, genomic ancestry did not interfere with therapy response. Among patients with rs12979860 T/T genotype, African genetic contribution was greater in the NR/R group (P = 1.51 × 10(-3) ), whereas Amerindian and European genetic ancestry contribution were higher in the SVR group (P = 3.77 × 10(-3) and P = 2.16 × 10(-2) respectively). Among HCV type 1 patients with rs8099917 T/T, African genetic contribution was significantly greater in the NR/R group (P = 5.0 × 10(-3) ); Amerindian and European ancestry genetic contribution were greater in the SVR group. CONCLUSION:IL28Brs12979860 and rs8099917 polymorphisms were predictors of therapy response in HCV genotypes 1, 2 and 3 subjects from an admixed population. Genomic ancestry did not interfere with response to therapy in patients with rs12979860 C/C, whereas it interfered in patients with C/T and T/T genotypes. Among HCV genotype 1 rs8099917 T/T patients, genomic ancestry interfered with response to therapy.
Authors: Raquel Francine Liermann Garcia; Simone Moreira; Ana Lucia de Araújo Ramos; Leslie Ecker Ferreira; Angelo Alves de Mattos; Cristiane Valle Tovo; Lysandro Alsina Nader; Juliene Antonio Ramos; Edson Rondinelli; Arnaldo de Jesus Dominici; Christian Evangelista Garcia; Mauro de Souza Leite Pinho; Carlos Eduardo Brandão-Mello; Cristiane Alves Villela-Nogueira; Paulo Henrique Condeixa de França Journal: World J Gastroenterol Date: 2013-11-14 Impact factor: 5.742
Authors: María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino Journal: BMC Med Date: 2013-01-08 Impact factor: 8.775
Authors: Bruna C Bertol; Simone Moreira; Raquel F L Garcia; Leslie E Ferreira; Guilherme Debortoli; Mauro de Souza Leite Pinho; Marcia Amendola-Pires; Alessandra M de Almeida Maciel; Carlos E Brandço-Mello; Paulo H C de França Journal: Front Microbiol Date: 2015-03-04 Impact factor: 5.640
Authors: Andréa Marques Vieira da Silva; Lucia Elena Alvarado-Arnez; Tamiris Azamor; Leonardo Ribeiro Batista-Silva; Thyago Leal-Calvo; Ohanna Cavalcanti de Lima Bezerra; Marcelo Ribeiro-Alves; Fernanda de Souza Gomes Kehdy; Patrícia Cristina da Costa Neves; Camilla Bayma; Jane da Silva; Alessandro Fonseca de Souza; Marcelo Muller; Elisabete Ferreira de Andrade; Ana Carolina Magalhães Andrade; Eliane Matos Dos Santos; Janaína Reis Xavier; Maria De Lourdes De Sousa Maia; Rolando Páez Meireles; Hugo Nodarse Cuni; Guilherme Becker Sander; Paulo Dornelles Picon; Denise C S Matos; Milton Ozório Moraes Journal: Front Cell Infect Microbiol Date: 2021-07-07 Impact factor: 5.293